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Lipoatrophic Diabetes : An Improved Procedure for the 
Isolation and Purification of a Diabetogenic 
Polypeptide from Urine 
By LAWRENCE H. LOUIS 
An improved procedure is outlined for 
the isolation of a diahetogenic polypep- 
tide from urine of patients with lipoa- 
trophic diabetes. The compound provokes 
insulin resistance and temporary loss of 
glucose tolerance when administered to 
dogs and humans. It is now free of a 
toxic contaminant which, by the previous 
method, had to he removed by more 
drastic treatment of the compound than 
was deemed suitable. Its physicochemical 
properties closely resemble those of a 
diahetogenic polypeptide isolated from 
the adenohypophyses of beef, sheep, and 
hog described previously from this lah- 
oratory. (Metabolism 18: No. 7, July, 
545-555, 1969) 
I N A PREVIOUS communication we described a method for isolating a diabetogenic polypeptide from the urine of patients with lipoatrophic 
diabetes.l This substance, designated as fraction 1, was shown to provoke 
insulin antagonism and loss of glucose tolerance when administered to dogs 
and men. Isolation of the compound and demonstration of its diabetogenic 
activities have now been confirmed.* However, interpretation of the results 
was somewhat clouded by the occurrance in man of mild toxic effects which 
included myalgia, cephalalgia and pyrexia. Further purification of the material 
was initially achieved by somewhat drastic treatment of the material with 
O.lN hydrochloric acid at a temperature of 100” C. From this solution an 
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active polypeptide (isoelectric point approximately 4.7) was isolated which 
gave no evidence of toxicity in man. This hydroIytic product was designated 
as Fraction III C2; and it was this fraction that was employed in most of our 
early anti-insulin studies in humans.’ 
The present report describes an improved procedure for isolation of the 
original diabetogenic polypeptide (fraction 1) which eliminates toxic con- 
taminants without requiring hydrolysis. In physicochemical properties the sub- 
stance resembles closely the diabetogenic polypeptide designated as fraction 
PI isolated from beef, sheep, and hog pituitary glands as recently reported 
from this laboratory .3-5 The isoelectric point of the polypeptide prepared by 
the present procedure is approximately pH 4.1 which is the same as that of 
the diabetogenic peptide obtained from the adenohypophyses of three species 
mentioned.5 It appears reasonable to assume that the urinary peptide had 
its origin in the pituitary gland.4 
MATERIALS AND METHODS 
Urine samples were collected and preserved as previously described.1 For the present 
studies, urine specimens from two patients (M.D. and T.R.) with lipoatrophic diabetes 
were employed. Both subjects had moderate proteinuria. 
The oxycellulose powder (17%~21% COOH, Eastman Chemical Products, Inc., Kings- 
port, Tenn.) was kept refrigerated and before use was washed successively with distilled 
water, O.lN HCl, and distilled water. 
Methods and procedures for glucose and insulin tolerance tests were carried out in the 
same manner as described in previous reports. l-4,5 Two healthy male volunteers without a 
family history of diabetes served as subjects. They were maintained on a constant high 
carbohydrate diet throughout the testing period. Solutions of the peptide were prepared 
for parenteral administration as previously described.1 
RESULTS 
Figure 1 outlines in detail the new procedure employed for isolation of the 
active polypeptide from urine. 
Table 1 shows the elemental composition of the compound obtained from 
the urine of patients M.D. and T.R. Each patient excreted approximately 12 
mg per day of the isolated peptide. 
Fraction 1 extracted from the urine of patient M.D. was tested for dia- 
betogenicity on six normal dogs and two humans. Figures 2-8 illustrate the 
diminished glucose tolerance induced in the dogs. The amount of the com- 
pound injected varied from l-4 mg. per kilogram body weight. In Dog P (Fig. 
2) and Dog R (Fig. 3) a significant decrease of glucose tolerance was evident 
after a single injection of 1 mg. per kilogram body weight. In Dog 0 abnormal 
glucose tolerance was still evident 34 hours after administration of the com- 
pound (Fig. 8). 
Insulin resistance was demonstrated on two normal dogs (Dog N and 
Dog 0). A single dose of 2 mg. per kilogram body weight was administered 
to Dog N. In Dog 0, a second dose of 4 mg. per kilogram body weight was 
administered 24 hours after the first injection of 3 mg. per kilogram body 
weight. Insulin tolerance tests were performed 10 hours after injection. These 
results are shown in Figs. 9 and 10. Both animals exhibited marked resistance 
LIPOATROPHIC DIABETES 547 
URINE 13-4 &ys coll~bnl 
adjust b pH 5.1 wilh tNHCI: dd 2 wt. of 4thanof: bt sbnd 
M-24 hrs; lilbr 
I 1 
PRECIPITATE 
wsh with MS ethanol at pH 5.1: dry at room lemperaturs: 





diust crretully b pH 5. I with I N&W; add 2 WI. ethanol: 




Idd 1 gm Iwhly *arhsd oxyullubse and stir 3-4 ho: decant 
and repeat with lgm oxycellulore onu more: cenWtup and 
lilter 
comblna olycellubre; wash wit0 dbt water: 
dd Wml a 1 N HCI and stir I-2 hrs.: tlnsr 
soLtnIoN 
put in mlkdion bq md dblyze qalnst dirt wter at 4°C: 








adiust b r4i 4 I: bi rbnd 








dissolve an M ml 0.1 N Hct: 





ldjust b ~“4.1: let rbnd 






dissoh’e pp1 in lmml (LMNHCI; put in 
wltcdion Lug md dirlpe winrt dirt water 
at 4’C: chmw IyIbr until cmnpbte 
pr#ciplCtion i Ipphilize Prsrtptble: dIsHlIve 
crude Mterbl in 3M3ml P(HN WI: 






adjust ta pH3.5-3.6 rlth D.D5N NOH: let stand 112-I hr. at P’C: 











dtssolw in 2Wg ml aD5N HCI: 
centrllups and Wter; rep& steps 
I2 and I3 once more: wash p,dcip,btr 
with dist #rater 3 tinm md Iqhilize 
Fig. 1 
M. D. I I R.T. 48.41 6.96 13.58 1.72 48.53 6.95 13.26 1. 59 
Table 1 .-Elemental Analysis 
of Fraction One Isolated from 
Urine of Patients with Lipo- 
atrophic Diabetes 


















DO0 P Q 7.9 Kg 
8mg (~WOMOM) 
@IO HR AFTER FRACTION1 
F w2 I I l/2 2 2 l/2 3 
HOURS 
Fig. 2 
to exogenous insulin and Dog 0 had a significantly elevated fasting blood 
sugar. No significant change in rectal temperature was observed. 
The biological effects of the polypeptide were also studied in two human 
volunteers (R.C.M. and G.W.). After control glucose and insulin tolerance 
tests had been obtained, a single dose of 25 mg. was administered intra- 
muscularly to each of the subjects. Glucose tolerance tests were then carried 
out daily for eight days except for the second day (45 hours) during which an 
insulin tolerance test was done. The results are presented in Tables 2 and 3. 
Table 4 shows the effect of the peptide upon ins&n toIerance 45 hours after 
injection. No significant changes in urinary 17-hydroxysteroids and 17-keto- 
steroids were observed in either subject. 
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Table 2.-Effect of Fraction One on Glucose Tolerance of Normal Subject (R.C.M., 
23 years, M, 84.8 Kg.) 
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Table 3.Effect of Fraction One on Glucose Tolerance of Normal Subject (R.C.M., 
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Table 4.Effect of Fraction One on Insulin Tolerance of Normal Subjects (Glucagon- 
free Insulin, 0.05 units/Kg.) 
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Fig. 8.-Dog 0 (F), 
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COMMENTS 
Isolation from urine of the active polypeptide by the present procedure 
appears to be more complete. In the previous method1 a substantial quantity 
of the active compound was still present in the acetic acid solution even after 
three successive treatments with oxycellulose. Because we were not aware of 
this, these solutions were discarded. This was very unfortunate because much 
of the peptide (isoelectric point, approximately pH 4.1) was lost. The toxic 
material was removed at pH 3.5-3.6 (step 12 of the new method). 
Disc electrophoresis of the active material reveals one prominent band to- 
gether with two minor ones. Further purification of this substance by Sephadex 
column chromatography is now in progress. 
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